Alaunos Therapeutics (TCRT – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares closed yesterday at $0.14.
According to TipRanks, Ramakanth is an analyst with an average return of -22.3% and a 21.24% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Affimed, Delcath Systems, and ImmunoGen.
The word on The Street in general, suggests a Hold analyst consensus rating for Alaunos Therapeutics.
See the top stocks recommended by analysts >>
Based on Alaunos Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4 thousand and a GAAP net loss of $8.77 million. In comparison, last year the company had a GAAP net loss of $9.93 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More on TCRT:
- Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)
- ZIOPHARM Oncology trading resumes
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
- ZIOPHARM Oncology trading halted, news pending
- TCRT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
